Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDMatinas Biopharma Holdings Inc Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 1 | -$1.32 | -$1.32 | -$1.32 |
| Q2 2026 | 1 | -$1.32 | -$1.32 | -$1.32 |
| Q3 2026 | 1 | -$1.50 | -$1.50 | -$1.50 |
| Q4 2026 | 1 | -$0.97 | -$0.97 | -$0.97 |
| Q1 2027 | 1 | -$1.69 | -$1.69 | -$1.69 |
| Q2 2027 | 1 | -$1.33 | -$1.33 | -$1.33 |
| Q3 2027 | 1 | -$1.68 | -$1.68 | -$1.68 |
| Q4 2027 | 1 | -$1.48 | -$1.48 | -$1.48 |
| Q1 2028 | 1 | -$1.27 | -$1.27 | -$1.27 |
| Q2 2028 | 1 | -$1.50 | -$1.50 | -$1.50 |
| Q3 2028 | 1 | -$1.52 | -$1.52 | -$1.52 |
| Q4 2028 | 1 | -$1.45 | -$1.45 | -$1.45 |
| Q1 2029 | 1 | -$1.50 | -$1.50 | -$1.50 |
| Q2 2029 | 1 | -$1.50 | -$1.50 | -$1.50 |
| Q3 2029 | 1 | -$1.25 | -$1.25 | -$1.25 |
| Q4 2029 | 1 | -$1.06 | -$1.06 | -$1.06 |
| Q1 2030 | 1 | -$0.78 | -$0.78 | -$0.78 |
Matinas Biopharma Holdings Inc Earnings Date And Information
Matinas Biopharma Holdings Inc last posted its earnings results on Friday, May 8th, 2026. The company reported $-0.3 earnings per share for the quarter, topping analysts' consensus estimates of $-1.3175 by $1.0175. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Matinas Biopharma Holdings Inc has generated $-2 earnings per share over the last year ($-2 diluted earnings per share) and currently has a price-to-earnings ratio of -0.31. Matinas Biopharma Holdings Inc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Matinas Biopharma Holdings Inc Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/08/2026 | Q1 2026 | -$1.32 | -$0.30 | 1.02 | $25.00 K | $0 |
| 03/31/2026 | Q4 2025 | -$0.78 | -$0.30 | 0.48 | $25.00 K | $0 |
| 11/10/2025 | Q3 2025 | N/A | -$0.40 | N/A | N/A | $0 |
| 08/14/2025 | Q2 2025 | N/A | -$1.03 | N/A | N/A | $0 |
| 05/15/2025 | Q1 2025 | N/A | -$0.33 | N/A | N/A | $0 |
| 04/15/2025 | Q4 2024 | -$0.78 | -$1.73 | -0.95 | $300.00 K | $0 |
| 11/13/2024 | Q3 2024 | -$1.05 | -$0.85 | 0.2 | $300.00 K | $0 |
| 08/14/2024 | Q2 2024 | -$0.83 | -$1.15 | -0.32 | $300.00 K | $0 |
| 05/09/2024 | Q1 2024 | -$0.03 | -$1.34 | -1.31 | N/A | $0 |
| 03/27/2024 | Q4 2023 | -$1.13 | -$1.22 | -0.09 | N/A | $0 |
| 11/08/2023 | Q3 2023 | -$0.03 | -$1.39 | -1.36 | N/A | $0 |
| 08/09/2023 | Q2 2023 | -$0.03 | -$1.39 | -1.36 | N/A | $0 |
| 05/10/2023 | Q1 2023 | -$1.50 | -$1.25 | 0.25 | N/A | $1.10 M |
| 03/15/2023 | Q4 2022 | -$1.00 | -$0.01 | 0.99 | N/A | $1.06 M |
| 11/02/2022 | Q3 2022 | -$1.50 | -$1.26 | 0.24 | N/A | $1.06 M |
| 08/11/2022 | Q2 2022 | -$1.50 | -$1.36 | 0.14 | N/A | $1.06 M |
| 05/12/2022 | Q1 2022 | -$1.50 | -$0.58 | 0.92 | N/A | $0 |
| 03/08/2022 | Q4 2021 | -$1.50 | -$1.55 | -0.05 | N/A | $-333 |
| 11/08/2021 | Q3 2021 | -$1.50 | -$1.59 | -0.09 | N/A | $0 |
| 08/10/2021 | Q2 2021 | -$1.00 | -$1.17 | -0.17 | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Matinas Biopharma Holdings Inc Earnings: FAQ's
In the previous quarter, Matinas Biopharma Holdings Inc (:MTNB) reported $-0.3 earnings per share (EPS) to beat the analysts' consensus estimate of $-1.3175 by $1.0175.
The conference call for Matinas Biopharma Holdings Inc's latest earnings report can be listened to online.
The conference call transcript for Matinas Biopharma Holdings Inc's latest earnings report can be read online.
Matinas Biopharma Holdings Inc (:MTNB) has a recorded net income of $-10,345,000.Matinas Biopharma Holdings Inc has generated $-2 earnings per share over the last four quarters.
Matinas Biopharma Holdings Inc (:MTNB) has a price-to-earnings ratio of -0.31 and price/earnings-to-growth ratio is -0.